← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
The Research Institute Of The Mcgill University Health Centre
$19,449,016
Total funding
27
Grants
Funding over time
peak $2.5M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$19,449,016 · 27
By mechanism
—$19,449,016 · 27
Investigators at The Research Institute Of The Mcgill University Health Centre
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
WIRELESS MICROSENSOR TO CONTINUOUSLY MONITOR COMPARTMENT PRESSURE IN TRAUMA VICTIMS$2,202,176
· FY2019 · Defense Health Agency
PRECISION NUTRITION INCREASES EFFICACY OF DNA-DAMAGING THERAPIES IN PROSTATE CANCER$1,520,491
· FY2022 · Department of the Army
A GENOMICS APPROACH TO STUDY MOLECULAR HETEROGENEITY IN THE PATHOGENESIS OF TYPE 2 DIABETES AND ITS COMPLICATIONS$1,283,555
· FY2017 · Department of the Army
IDENTIFYING DRIVERS OF THERAPY RESISTANCE WITHIN THE TUMOR MICROENVIRONMENT OF ESOPHAGEAL ADENOCARCINOMA$1,192,313
· FY2021 · Defense Health Agency
DEVELOPMENT OF NEW THERAPEUTICS TARGETING BIOFILM FORMATION BY THE OPPORTUNISTIC PULMONARY PATHOGENS PSEUDOMONAS AERUGINOSA AND ASPERGILLUS FUMIGATUS$1,123,441
· FY2016 · Department of the Army
IDENTIFICATION OF PROSTATE CANCER PROGNOSTIC MARKERS$1,119,034
· FY2011 · Department of Defense
DEVELOPMENT OF CD109 AS A NOVEL TGF-BETA ANTAGONIST AND ANTI-FIBROTIC AGENT FOR THE TREATMENT OF SCLERODERMA$1,003,844
· FY2013 · Department of Defense
USP19 AS A NOVEL THERAPEUTIC TARGET FOR IMPEDING PROPAGATION AND SECRETION OF TAU IN PARKINSON'S DISEASE$999,531
· FY2018 · Department of the Army
REMOVING BARRIERS TO FULL RECOVERY$991,457
· FY2014 · Department of Defense
PARATHYROID HORMONE-RELATED PEPTIDE (PTHRP) AS A NEW TARGET FOR METASTATIC BREAST CANCER: EVALUATION IN PRECLINICAL MODELS$890,870
· FY2015 · Department of the Army
STAT6-DEPENDENT BRIDGING OF INNATE AND TH2 ADAPTIVE IMMUNITY IN THE LUNG$824,382
· FY2015 · Department of the Army
NETWORK FOR RARE TUMORS OF THE OVARY (NRTO)$678,770
· FY2021 · Defense Health Agency
PROTECTIVE EFFECT OF FENRETINIDE AGAINST SPINAL CONTUSION INJURY$642,236
· FY2010 · Department of Defense
DISCREET AND WEARABLE MICROWAVE SENSING FOR CONTINUOUS REAL-TIME BLADDER MONITORING$587,973
· FY2025 · Defense Health Agency
THE ROLE OF OSR1 IN BLADDER DYSFUNCTION FROM SPINAL CORD INJURY$539,611
· FY2021 · Defense Health Agency
BUILDING A RAPID DRUG DISCOVERY PIPELINE SPECIFIC FOR PEDIATRIC ACUTE MYELOGENOUS LEUKEMIA WITH MACHINE LEARNING/IN VITRO FEEDBACK LOOPS$524,340
· FY2025 · Defense Health Agency
STAT6-DEPENDENT BRIDGING OF INNATE AND TH2 ADAPTIVE IMMUNITY IN THE LUNG$517,127
· FY2015 · Department of the Army
EXPLORE THE IMPACT OF MICROBIOME IN THE RESPONSE OF THE COMBINATION OF RADIATION WITH IMMUNE CHECKPOINT BLOCKADE IN MUSCLE-INVASIVE BLADDER CANCER$498,789
· FY2020 · Department of the Army
DEVELOPING NEXT GENERATION OF PROGNOSTIC TOOLS FOR LOCALIZED CLEAR CELL RENAL CELL CARCINOMA THROUGH INTEGRATION OF GENOMIC, CLINICAL, AND PATHOLOGICAL FEATURES$416,115
· FY2024 · Defense Health Agency
NOVEL AMINOGLYCOSIDE THERAPY OF NONSENSE MUTATIONS IN POLYCYSTIC KIDNEY DISEASE$261,400
· FY2020 · Defense Health Agency